Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evolus Inc
(NQ:
EOLS
)
15.86
+0.38 (+2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus Inc
< Previous
1
2
3
4
5
6
Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Evolus
Via
Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
July 31, 2024
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss.
Via
Investor's Business Daily
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
July 31, 2024
From
Evolus
Via
Business Wire
Evolus: Chiseling Away At The Aesthetic Market
May 25, 2024
Via
Talk Markets
Recap: Evolus Q4 Earnings
March 07, 2024
Via
Benzinga
Evolus to Hold Investor Day on September 12, 2024
July 31, 2024
From
Evolus
Via
Business Wire
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia
July 30, 2024
From
Evolus, Inc.
Via
Business Wire
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference
July 25, 2024
From
Evolus
Via
Business Wire
Evolus to Report Second Quarter Financial Results on July 31, 2024
July 17, 2024
From
Evolus
Via
Business Wire
Evolus Announces Appointment of Albert G. White III to Board of Directors
July 01, 2024
From
Evolus
Via
Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
June 24, 2024
From
Evolus
Via
Business Wire
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
June 12, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Evolus
Via
Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
May 20, 2024
From
Evolus
Via
Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
May 15, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Evolus
Via
Business Wire
Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
May 10, 2024
From
Evolus, Inc.
Via
Business Wire
EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
EOLS stock results show that Evolus beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Evolus Reports First Quarter 2024 Results and Provides Business Update
May 07, 2024
From
Evolus
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 02, 2024
Pre-market stock movers are worth checking out with our coverage of all the latest and greatest news happening on Thursday!
Via
InvestorPlace
Evolus to Report First Quarter Financial Results on May 7, 2024
April 23, 2024
From
Evolus
Via
Business Wire
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
April 17, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From
Evolus
Via
Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From
Evolus
Via
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
Evolus
Via
Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.